Uri Lopatin

Uri is an Operating Partner at Khosla Ventures, where he focuses on biotech and life sciences. 

Prior to KV, Uri was the founding CEO of Pardes Biosciences (NASDAQ:PRDS), a biotech focused on utilizing reversible-covalent chemistry to develop small molecule oral antivirals for the treatment and prevention of SARS-CoV2 infections. Uri led Pardes from conception through phase 1 and its public listing via SPAC.

Before Pardes Biosciences, Uri was a visiting group partner at Y Combinator where he focused on their biotech portfolio companies.  This followed  his role as founder and Chief Medical Officer at Assembly Biosciences (NASDQ:ASMB) an antiviral company developing novel therapies for chronic HBV. Prior to his entrepreneurial endeavors, Uri ran clinical and translational programs at Schering-Plough, Roche, and Gilead Sciences.

Uri holds a bachelor’s degree cum laude in biology from Cornell University. He obtained his MD from the University of Medicine and Dentistry of NJ – NJ Medical School; completed his internal medicine training at the University of Washington and New York University Medical Center; and his board certification in Infectious Diseases at the National Institutes of Health where his research focus was on viral mucosal immunology.